Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High – Should You Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $6.71 and last traded at $6.52, with a volume of 2383363 shares traded. The stock had previously closed at $6.40.

Analyst Ratings Changes

Several analysts have issued reports on CMPX shares. Lifesci Capital initiated coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price for the company. William Blair assumed coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating for the company. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research note on Tuesday, January 6th. JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Finally, Compass Point set a $10.00 price target on shares of Compass Therapeutics in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Price Performance

The company has a market cap of $1.16 billion, a PE ratio of -14.49 and a beta of 1.46. The company’s 50 day simple moving average is $5.49 and its two-hundred day simple moving average is $4.30.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. Sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of CMPX. Victory Capital Management Inc. raised its holdings in shares of Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after buying an additional 2,164 shares during the period. Focus Partners Wealth increased its stake in Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Compass Therapeutics by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after purchasing an additional 3,329 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Compass Therapeutics during the fourth quarter worth about $32,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.